Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07169578 · ClinicalTrials.gov registry record · Phase 3
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
A Phase 3 study of Alzheimers Disease, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
- 20
- Study locations
NCT07169578: Recruiting Phase 3 study of Alzheimers Disease, sponsored by Hoffmann-La Roche.
NCT07169578 is a Phase 3 study of Alzheimers Disease that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 800 participants, below the 3,921-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07169578, a Phase 3 study of Alzheimers Disease, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Trontinemab
Study Locations (20)
Florida
- K2 Medical Research - The Villages - Lady Lake
- K2 Medical Research, LLC - Maitland
- Renstar Medical Research - Ocala
- Axiom Brain Health LLC - Tampa
- Charter Research - Lady Lake/The Villages - The Villages
- Alzheimer?s Research and Treatment Center - Wellington
- Conquest Research, LLC - Winter Park
California
- Inglewood Clinicals - Inglewood
- Irvine Center for Clinical Research - Irvine
- UCSF - Memory and Aging Center - San Francisco
- Syrentis Clinical Research - Santa Ana
New York
- Basil Clinical - Laurelton
- Adams Clinical Harlem - New York
Arizona
- Banner Sun Health Research Institute - Sun City
Georgia
- Accel Research Sites-NeuroStudies - Decatur
Hawaii
- Hawaii Pacific Neuroscience - Honolulu
Illinois
- RE:Cognition (Chicago) - Chicago
Massachusetts
- Boston Center for Memory - Newton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2025-09-17 |
| Est. Completion | 2028-06-07 |
| Phase | Phase 3 |
What NCT07169578 shows while recruiting
NCT07169578 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, below the 3,921-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07169578 names 20 study sites across 10 states, led by Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT07169578 about?
NCT07169578 is a clinical study titled "A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease". The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
What is the current status of trial NCT07169578?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2025-09-17. Estimated completion is 2028-06-07.
What conditions does trial NCT07169578 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT07169578?
The interventions under investigation include: Placebo (OTHER), Trontinemab (DRUG).
Who is sponsoring clinical trial NCT07169578?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07169578 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07169578's enrollment target sits among peer trials
800 19th of 147 higher than 127 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
RECRUITING · Phase 3
-
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI